

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 2D




Fig. 3A




Fig. 3B




Fig. 3C




Fig. 3D




Fig. 4




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 5E




Fig. 5F




Fig. 5G




Fig. 5H



merge
WGA + IgG
IgG
myc
merge
WGA + A1
A1
myc
merge
WGA + A2
A2
myc
merge
WGA + A3
A3
myc
merge
WGA + A4
A4
myc
merge
WGA + A5
A5
myc
merge
WGA + A6
A6
myc
merge
WGA + A7
A7
myc

Fig. 6A



hTRPM4 current under hypoxia at ± 80 mV
0 min
7 min
Current (pA)
300
200
100
0
-100
-200
-300
IgG -80
A1 -80
A2 -80
A3 -80
A4 -80
A5 -80
A6 -80
A7 -80
IgG +80
A1 +80
A2 +80
A3 +80
A4 +80
A5 +80
A6 +80
A7 +80
A1 - Chimeric antbody, A2 - A7 - humanized antbody

Fig. 6B



% of inhibition
120
90
60
30
0
0
1
2
3
4
5
6
7
8
9
10
A2 µg/ml

Fig. 6C



VH+VL
VH1+VL1
VH1+VL3
VH2+VL1
RU
Relative response
Time
s
0
10
20
30
40
250
500

Fig. 7